MedPath

Role of Choline PET/CT in Predicting Survival in Patients With Hepatocellular Carcinoma

Completed
Conditions
Hepatocellular Carcinoma
Registration Number
NCT03430635
Lead Sponsor
Humanitas Clinical and Research Center
Brief Summary

¹¹C-choline positron emission tomography/computed tomography (PET/CT) has been used in patients with some types of solid cancers, but few data are available in patients undergoing hepatectomy for hepatocellular carcinoma (HCC). The aim of this study was to analyze the prognostic value of metabolic imaging data by using ¹¹C-choline PET/CT in patients with HCC before hepatectomy.

Detailed Description

Our prospectively maintained liver unit database was queried for patients with HCC preoperatively staged with ¹¹C-choline PET/CT. This metabolic imaging modality was performed in addition to standard abdominal CT or magnetic resonance imaging. Several PET/CT parameters were recorded and analyzed. Univariate and multivariate analyses were performed to identify whether those PET/CT parameters could be predictors of overall survival (OS) and disease-free survival (DFS) of HCC patients.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Any patient with HCC candidate to surgical resection preoperatively staged with ¹¹C-choline PET/CT
Exclusion Criteria
  • R2 resection;
  • Intraoperative use of RFA/MWI
  • Postoperative death (90-days)

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Identification of PET/CT parameters that can be predictors of survivalFrom date of surgery until the date of first documented progression or date of death from any cause, whichever came first assessed up to 72 months

Identification of specific PET/CT parameters that can be used as independent predictors of overall and/or disease-free survival

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath